Sign up to save your podcasts
Or
Share PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.
View all episodes
By Joe BrunettoIn this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.